Nourkrin® Woman with Marilex® Enhances Hair Growth and Appearance and Improves Hair Confidence in Women with Diffuse Hair Loss from Brazil: An Investigatorinitiated Clinical Study

Background: Female Pattern Hair Loss (FPHL) and Telogen Effluvium (TE) are common dermatological conditions in women, affecting half of the female population. Treating hair loss in women is more challenging since its pathogenesis is not fully understood and it commonly leads to more serious psychosocial consequences compared to hair loss in men. Recent evidence highlights the involvement of proteoglycan dysmetabolism and follicular hypoglycania as a mediating pathology. Follicular hypoglycania disturbs cellular activity and is behind the gradual deterioration of hair follicles, a condition known as Proteoglycan Follicular Atrophy (PFA). Proteoglycan Replacement Therapy (PRT) with Nourkrin® with Marilex® is a unique approach that helps to treat PFA and restore a normal hair growth cycle. Methods: We aimed to investigate the treatment satisfaction and subjective efficacy of Nourkrin® with Marilex®. To this end, 67women with moderate to severe FPHL or TE (mean age=42.73 years) were enrolled into an investigatorinitiated, subjective, cohort study carried out by practicing dermatologists in Brazil in collaboration with the World Hair Council. Study participants were randomly selected by several collaborating dermatologists and have voluntarily started a 6 month course of monotherapy with Nourkrin® Woman (600mg Marilex® per day). They were interviewed every 3 months using a semi-structured questionnaire. Results: Just after 3 months, 94.03% and 95.52% of participants reported having experienced improved hair growth and appearance, respectively; and 83.58% were more confident with their hair. All Nourkrin® users were satisfied with the results at this point and were willing to continue with the treatment. At endpoint, 94.03% of subjects experienced enhanced hair growth and 92.54% reported improved appearance of their hair. These positive changes have led 83.58% of participants to feel more confident with their hair. Overall treatment satisfaction rate with Nourkrin® therapy was 97.01%. Conclusion: Our findings indicate that women with diffuse hair loss found PRT with Nourkrin® an effective approach that stimulates hair growth and improves hair appearance. Treated patients felt more self-confident and were satisfied with Nourkrin® monotherapy. Avens Publishing Group Inviting Innovations Citation: Mattos Simoes M, Thom E, Wadstein J. Nourkrin® Woman with Marilex® Enhances Hair Growth and Appearance and Improves Hair Confidence in Women with Diffuse Hair Loss from Brazil: An Investigator-initiated Clinical Study. J Clin Investigat Dermatol. 2020;8(1): 4 J Clin Investigat Dermatol 8(1): 4 (2020) Page 02 ISSN: 2373-1044 thinning has led to the utilisation of proteoglycan-based therapies as a novel approach to hair loss. The Originator Nourkrin® with Marilex®(produced by Pharma Medico Aps, Aarhus, Denmark) uses a specific combination of bioactive proteoglycans with ‘anagen inducing’ and ‘anagen maintaining’ properties to mitigate FHG and treat PFA. This unique method is referred to as ‘Proteoglycan Replacement Therapy (PRT)’ in clinical literature. Numerous clinical trials and papers have confirmed and demonstrated the clinical efficacy and safety of PRT with Nourkrin® in patients with diffuse hair loss [6-9]. In order to provide a more complete picture of the therapeutic effects, tolerability and treatment satisfaction rate of PRT with Nourkrin®, a clinical cohort study by practicing dermatologists was carried out. We have strived in this research to elucidate how the objective clinical improvements by Nourkrin® are subjectively perceived by patients. Materials and Methods